Cited by 119Dementia and Cognitive Impairment ResearchAdvanced MRI Techniques and ApplicationsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Decreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1 H-MRS at 0.5 T

Abstract

OBJECTIVE: To determine whether glutamate + glutamine (GLX) levels in the brain as measured in vivo with proton MRS at 0.5 tesla (T) distinguish between probable Alzheimer's disease and normal aging. BACKGROUND: Glutamatergic markers had been measured previously in postmortem brain tissue. Conventional proton MRS at 1.5 T cannot reliably detect the GLX resonance in vivo. The authors developed a technique at 0.5 T that is sensitive to the GLX resonance. METHODS: Metabolite ratios using creatine and phosphocreatine resonance as an internal standard were acquired from the cingulate region of 18 patients with AD and 12 healthy controls. The major resonances in the spectrum were examined: N-acetylaspartate (NAA), choline-containing compounds, myo-inositol, and GLX. The Mini-Mental State Examination (MMSE) was used to assess cognitive status. The Instrumental Activities of Daily Living Scale (Instrumental ADL) was used to assess functional status. RESULTS: Reduced ratios of GLX (-10%, p = 0.001) and NAA (-12%, p = 0.000) were found in patients with AD. Increased ratios of myo-inositol in patients with AD approached significance (+14%). GLX ratios of patients with AD were correlated with MMSE (r = 0.61, p = 0.007) and Instrumental ADL (r = 0.59, p = 0.01) scores. The combined sensitivity of NAA and myo-inositol in correctly diagnosing AD was 78%. The addition of GLX to NAA and myo-inositol increased the sensitivity to 89%. Overall diagnostic accuracy improved from 80 to 83% with the addition of GLX. CONCLUSIONS: Glutamate + glutamine reduction may be a biologic marker for AD and may be a potential aid in the early clinical diagnosis of AD.

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.56.6.737

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. Hugon J Vallat JM, Dumas M. Role of glutamate and excitotoxicity in neurologic diseases. Rev Neurol (Paris) . 1996; 152: 239–248.
  2. Braak H, Griffing K, Braak E. Neuroanatomy of Alzheimer’s disease. Alzheimer Res . 1997; 3: 235–247.

Cited by

Sorted by citations

See all 119

Metadata

Authors
Antuono, P. G., Jones, J. L., Wang, Y., & Li, S.-J.
Affiliations
Medical College of Wisconsin (US)
Venue
Neurology
Published
2001-03-27
Volume
56
Issue
6
Pages
737-742
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2101563929
Cited by
119
References
42
Citations by year
2026: 6 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 7 · 2016: 4 · 2015: 3 · 2014: 8 · 2013: 5 · 2012: 6
FWCI
2.37
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Center for Research Resources (5M01-RR00058, M01RR000058)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, glutamate/glutamine, 1H NMR, 0.5T MRI, N-acetylaspartate, myo-inositol, brain metabolites, diagnostic biomarkers, early diagnosis, normal aging, cingulate cortex
MeSH terms
Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Glutamine, Humans, Male, Middle Aged, Magnetic Resonance Spectroscopy, Protons, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review